Eli Lilly and Compan

LLY
Delayed Nyse - 10/16 10:03:01 pm
107.95USD
-1.6%
Prev.109.7000
Open109.1800
High109.4800
Low107.7900
Volume1 349 646
Financials
Sales 2019 22 229 M
EBIT 2019 6 071 M
Net income 2019 8 146 M
Debt 2019 12 101 M
Yield 2019 2,34%
P/E ratio 2019 12,3x
P/E ratio 2020 16,9x
EV / Sales2019 4,99x
EV / Sales2020 4,53x
Capitalization 98 821 M
Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (47.6%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (17.4%);
- veterinary medicine (12.8%);
- cardiovascular...
Sector :
Pharmaceuticals - NEC
Calendar :
2019-10-23 Earnings Release
Trading Rating :
Investor Rating :
Latest news
10/16ELI LILLY AND : Terns pharmaceuticals to present positive preclinical data on fxr agonist tern-101 at the liver meeting 2019
AQ
10/16ELI LILLY AND : Phase 3 Pegilodecakin Study Misses Main Endpoint in Pancreatic Cancer
DJ
10/16ELI LILLY AND : Lilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survival
PU
10/15ELI LILLY AND : Correction to Eli Lilly Promoting Women Article on Oct. 15 -- Journal Report
DJ
10/15ELI LILLY AND : Inside Eli Lilly's Successful Strategy to Promote More Women -- Journal Report
DJ
10/14ELI LILLY AND COMPANY : - Lilly's REYVOW, The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval
AQ
10/14ELI LILLY AND : PhRMA - Remembering Harrison Cook, Vice President for International Government Affairs at Eli Lilly and Company
AQ
10/14ELI LILLY AND COMPANY : - Lilly Presents Positive Results for Taltz in Pediatric Patients with Moderate to Severe Plaque Psoriasis
AQ
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishNeutralBearish
Resistance111120118
Spread/Res.-3,1%-9,9%-8,8%
Spread/Supp.1,1%1,1%1,1%
Support107107107